News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kadimastem To Collaborate With Merck Serono To Advance Combined Efforts In Neurodegenerative Disease Area



8/4/2014 11:11:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel--(BUSINESS WIRE)--Israeli biotechnology company Kadimastem (TASE:KDST) reports that it has signed a collaboration agreement with Merck to carry out drug screening in the neurodegenerative diseases space for multiple sclerosis (MS), and potential other neurodegenerative diseases. Kadimastem will utilize its unique platform for Merck Serono, the biopharmaceutical division of Merck, for the screening of new compounds as potential new therapeutics.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES